NATtrol™ SARS-Related Coronavirus 2 Variant B.1.351 Stock (1mL)
- Volume: 1.0mL
- Units/Pack: 1
- Storage Condition: 2-8°C
- Hazardous Information: Non-Infectious
- Matrix: Purified protein matrix treated with 0.09% sodium azide
- Target: 1,000,000 copies/mL
- Product Type: Inactivated Organism
-
Classification/ Permits:
RUO
Learn MoreXFor Research Use Only. Not for use in Diagnostic Procedures.
Description
ZeptoMetrix external quality controls and verification panels have demonstrated performance on a variety of molecular platforms. Based upon the platform and assay’s product configuration, including but not limited to fill volumes and concentrations of analytes, we recommend our NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock to be used in conjunction with a real-time PCR thermal cycler. NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock includes SARS-CoV-2, Isolate South Africa/KRISP-K005325/2020.
- Formulated with purified, intact organisms
- Organisms are chemically modified to render them noninfectious
- Refrigerator stable—store between 2 and 8°C
- Purified protein matrix treated with 0.09% sodium azide
- For determination of the presence of SARS-CoV-2 Variant B.1.351 nucleic acids
- 1.0 mL vial
- Target concentration of 1,000,000 copies/mL
Intended Use
NATtrol products are ready-to-use, inactivated full process controls designed to evaluate performance of molecular tests. They can be used for verification of assays, training of laboratory personnel and to monitor assay-kit lot performance. NATtrol products contain intact organisms and should be run in a manner similar to clinical specimens.
Limitations
(SARS-CoV-2) Variant B.1.351 Stock (1mL) is for research use only. Not for use in diagnostic procedures. Quality control materials should be used in accordance with local, state, federal, and accreditation requirements. This product is not intended to replace the manufacturer's controls provided with the assay. Propagation or commercialization are prohibited without prior written consent from Antylia Scientific.
When used as a control for nucleic acid tests, the same protocols as those used to amplify extracted clinical specimens should be employed.
The suitability and performance characteristics should be determined by your laboratory for each intended usage.
